Spatiotemporally Ultrasound‐Controlled Nanoparticles Reprogramming Immunostimulatory Antigen‐Presenting Cancer‐Associated Fibroblasts to Enhance Cancer Immunotherapy
Advanced Science · 2026
DOI: 10.1002/advs.76673 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Chen Ai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Qilu Hospital of Shandong University, Jinan, Shandong, People's Republic of China. Hauptthemen laut MEDLINE: Nanoparticles, Immunotherapy, Cancer-Associated Fibroblasts. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer‐associated fibroblasts (CAFs) are a major component of the tumor microenvironment and represent a potential therapeutic target for fibrotic breast cancer. Myofibroblastic CAFs (myCAFs), the major subtype, form a tumor barrier by generating a dense extracellular matrix (ECM) that greatly limits the penetration of immune cells and promotes an immunosuppressive microenvironment. Reprogramming the immunosuppressed myCAFs into the immune activated antigen presenting CAF (apCAFs), rather than directly eliminating CAFs, is a better treatment modality. We developed a spatiotemporally ultrasound‐controlled nanoparticle (mRNA/V@M NPs) based on a lipid‐polymer hybrid drug delivery platform to co‐encapsulate CD74 mRNA and V‐9302. Interestingly, this study found that successfully reprogrammed myCAFs could activate CD4 + T cells, reduce the ECM, and promote immune cell infiltration through the CD74‐MHC II pathway. To overcome the limitation of MHC I immunodeficiency, V‐9302 was used to induce immunogenic cell death (ICD) in tumor cells and activate dendritic cells (DCs) to compensate for MHC I‐mediated immunodeficiency. In conclusion, in a fibrotic triple‐negative breast cancer mouse model, mRNA/V@M NPs combined with ultrasound treatment significantly enhanced MHC I and MHC II activation and increased CD8 + T cell infiltration and suppressed immunosuppressive TME, thereby triggering robust systemic antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Qilu Hospital of Shandong University, Jinan, Shandong, People's Republic of China.
- Translational Medicine Research Center in Nano Molecular and Functional Imaging of Shandong University, Jinan, People's Republic of China.
- Research Center for Basic Medical Sciences, Qilu Hospital of Shandong University, Jinan, People's Republic of China.
- Shandong Key Laboratory of Magnetic Field-Free Medicine & Functional Imaging, Shandong University, Jinan, Shandong, People's Republic of China.
- Research Institute of Magnetic Field-Free Medicine & Functional Imaging, Shandong University, Jinan, Shandong, People's Republic of China.
- National Medicine-Engineering Interdisciplinary Industry-Education Integration Innovation Platform, Shandong University, Jinan, Shandong, People's Republic of China.
ORCID-Profile: Dexin Yu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ai, C., Sun, W., Zhao, Y., Sun, D., Meng, T., Qi, Y., Jiang, F., Sun, J., Gao, Z., & Yu, D. (2026). Spatiotemporally Ultrasound‐Controlled Nanoparticles Reprogramming Immunostimulatory Antigen‐Presenting Cancer‐Associated Fibroblasts to Enhance Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.76673
Vancouver
Ai C, Sun W, Zhao Y, Sun D, Meng T, Qi Y, et al. Spatiotemporally Ultrasound‐Controlled Nanoparticles Reprogramming Immunostimulatory Antigen‐Presenting Cancer‐Associated Fibroblasts to Enhance Cancer Immunotherapy. Advanced Science. 2026. doi:10.1002/advs.76673
BibTeX
@article{Ai2026,
author = {Ai, Chen and Sun, Weikai and Zhao, Yuxuan and Sun, Daqian and Meng, Ting and Qi, Yafei and Jiang, Fengyang and Sun, Jintang and Gao, Zhiliang and Yu, Dexin},
title = {Spatiotemporally Ultrasound‐Controlled Nanoparticles Reprogramming Immunostimulatory Antigen‐Presenting Cancer‐Associated Fibroblasts to Enhance Cancer Immunotherapy},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76673}
}
EUVIMED